BFRI logo

BIOFRONTERA INC

BFRINASDAQ
🏆 #4828 by market capUS Equity
$959.81▲ $79.38 (+8.27%)
Simulated price
🔔
Track BFRI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.3%
7d▲ 83000.4%
14d▲ 79884.2%
30d▲ 61823.2%
ytd▲ 159868.3%
1y▲ 99002.7%
🏦Market Cap
$17M
Small Cap
📈Revenue Growth (YoY)
+17.8%
Healthy
📊Gross Margin
79.3%
High
💵FCF Margin
—
⚖️P/S Ratio
0.4x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$953.41 – $968.44
52-Week Range
$0.56 – $1.66
Volume
$3.02B
Avg Volume
$3.89B
Shares Outstanding
12.8M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$46M
Last Q Revenue
$11M
P/E Ratio
—
P/S Ratio
0.4x
EPS (TTM)
$-0.59
Dividend Yield
—
Dilution (1yr)
+111.2%

Why Investors Own BFRI

  • ✓High-growth profile — revenue up +59.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 77% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BFRI logo

BIOFRONTERA INC

BFRI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$42M▲ +11.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.7%▲ +56.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −46.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▲ +29.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.6M▲ +111.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$231K▼ −$752K YoY
StockOtter · stockotter.space

About BIOFRONTERA INC

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$959.06
▼ −0.1% Downside
High Target$1,044.32
Low Target$763.04
Based on 23 analysts

Latest News & Updates

🚀
CNBC·2h ago

BIOFRONTERA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift BFRI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

BIOFRONTERA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.